Influence of both salvage and DNA damage response pathways on resistance to chemotherapeutic antimetabolites

Biochemical Pharmacology

Volumn 52, Issue 3, 1996, Pages 425-431

  Pickard, Mark ^a   Kinsella, Anne ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

antimetabolites; dipyridamole; drug resistance; salvage pathways

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; COBALT 60; DIPYRIDAMOLE; FLUOROURACIL; HYPOXANTHINE; METHOTREXATE; SPARFOSIC ACID; THYMIDINE; URIDINE;

ARTICLE; BIOSYNTHESIS; CELL IMMORTALIZATION; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG RESISTANCE; DRUG SENSITIVITY; EMBRYO; FIBROBLAST; HUMAN; HUMAN CELL; ONCOGENE RAS; PRIORITY JOURNAL; PURINE METABOLISM; PYRIMIDINE METABOLISM;

EID: 0030576665     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00244-4     Document Type: Article

References (43)

1. 1. Fox M, Boyle JM and Kinsella AR, Nucleoside salvage and resistance to antimetabolite anticancer agents. Br J Cancer 64: 428-436, 1991.
2. 2. Wright JA, Smith SH, Watt FM, Hancock MC, Hudson DL and Stark GR, DNA amplification is rare in normal human cells. Proc Natl Acad Sci 87: 1791-1795, 1990.
3. 3. Weber G, Biochemical strategy of cancer cells and the design of chemotherapy. G.H.A. Clowes Memorial Lecture. Cancer Res 43: 3466-3492, 1983.
4. 4. Schimke RT, Alt FW, Kellems RE, Kaufman RJ and Bertino JR, Amplification of dihydrofolate reductase genes in methotrexate-resistant cultured mouse cells. Cold Spring Harbor Symp. Quant Biol 42: 649-654, 1977.
5. 5. Wahl GM, Paggett RA and Stark GR, Gene amplification causes over production of the first three enzymes of UMP synthesis in N-(phosphonacetyl)-L-aspartate-resistant hamster cells. J Biol Chem 254: 8679-8685, 1979.
6. 6. Kinsella AR and Haran MS, Decreasing sensitivity to cytotoxic agents parallels increasing tumourigenicity in human fibroblasts. Cancer Res 51: 1855-1859, 1991.
7. 7. Berlin RD and Oliver JM, Membrane transport of purine and pyrimidine bases and nucleosides in animal cells. Int Rev Cytol 42: 287-336, 1972.
8. 8. Plagemann PG and Wohlhueter RM, Permeation of nucleosides, nucleic acid bases and nucleotides in animals cells. Curr Topics Membrane Transp 14: 225-330, 1980.
9. 9. Young JP and Jarvis SM, Nucleoside transport in animal cells. Rev Biosci Res 3: 309-322, 1983.
10. 10. Kubler W, Spieckermann PG and Bretschneider HJ, Influence of dipyridamole (Persantin) on myocardial adenosine metabolism. J Mol Cell Cardiol 1: 23-38, 1970.
11. 11. Plagemann PG and Kraup M, Inhibition of nucleoside and nucleobase transport and nitrobenzylthioinosine binding by dilazep and hexobendine. Biochem Pharmacol 35: 2559-2567, 1988.
12. 12. Plagemann PGW, Nucleoside transport by Novikoff rat hepatoma cells growing in suspension culture. Specificity and mechanism of transport reactions and relationship to nucleoside incorporation into nucleic acids. Biochem Biophys Acta 233: 688-701, 1971.
13. 13. Zhen Y-S, Lui MS and Weber G, Effects of Acivicin and dipyridamole on hepatoma 3924A cells. Cancer Res 43: 1616-1619, 1983.
14. 14. Scholtissek C, Studies on the uptake of nucleic acid precursors into cells in tissue culture. Biochem Biophys Acta 158: 435-447, 1968.
15. 15. Grem JL and Fischer PH, Augmentation of 5-fluorouracil cytotoxicity in human cancer cells by dipyridamole. Cancer Res 45: 2967-2972, 1985.
16. 16. Kessel D and Dodd DC, Effects of persantin on several transport systems of murine leukemia cells. Biochem Biophys Acta 288: 190-194, 1972.
17. 17. Dive C and Hickman JA, Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 64: 192-196, 1991.
18. 18. Nelson WG and Kastan MB, DNA strand breaks: the DNA template alterations that trigger p53-dependent-DNA damage response pathways. Mol Cell Biol 14: 1815-1823, 1994.
19. 19. Namba M, Nishitani K, Fukushima F and Kimoto T, Multistep carcinogenesis of normal human fibroblasts. Anticancer Res 8: 947-958, 1988.
20. 20. Kinsella AR, Fiszer-Maliszewska L, Mitchell ELD, Guo YP, Fox M and Scott D, Introduction of the activated N-ras oncogene into human fibroblasts by retroviral vector induces morphological transformation and tumourigenicity. Carcinogenesis 11: 1803-1809, 1990.
21. 21. Pickard M, Dive C and Kinsella AR, Differences in resistance to 5-FU as a function of cell cycle delay and not apoptosis. Br J Cancer 72: 1389-1396, 1995.
22. 22. Fritsche M, Haessler C and Brander G, Induction of nuclear accumulation of the tumour suppressor protein p53 by DNA-damaging agents. Oncogene 8: 307-318, 1993.
23. 23. Voet D and Voet JG, Biochemistry, pp. 815-816. John Wiley and Sons, New York, Chichester, Brisbane, Toronto, Singapore, 1995.
24. 24. Sommer A and Santi DV, Purification and amino acid analysis of an active site peptide from thymidylate synthetase containing covalently bound 5′-fluoro-2′-deoxyuridylate and methylene tetrachloride. Biochem Biophys Res Commun 57: 689-696, 1974.
25. 25. Parker WB and Cheng YC, Metabolism and mechanism of action of 5-fluorouracil. Pharmac Ther 48: 381-395, 1990.
26. 26. Cheng YC and Nakayama K, Effects of 5-fluoro-2′-deoxyuridine on DNA metabolism HeLa cells. Mol Pharmocol 23: 171-174, 1983.
27. 27. Yoshioka A, Tanaka S and Hiraoka O, Deoxyribonucleoside triphosphate imbalance-fluorodeoxyuridine induced DNA double strand breaks in mouse FM3A cells and the mechanisms of cell death. J Biol Chem 262: 8235-8241, 1987.
28. 28. Kanamaru R, Kakuta H and Sato T, The inhibitory effects of 5-fluorouracil on the metabolism of preribosomal and ribosomal RNA in L-1210 cells in vitro. Cancer Chemother Pharmacol 17: 43-46, 1986.
29. 29. Carrico CK and Glazer RI, The effect of 5-fluorouracil on the synthesis and translation of poly(A) RNA from regenerating liver. Cancer Res 39: 3694-3701, 1979.
30. 30. Dolnick BJ and Pink JJ, Effects of 5-fluorouracil on dihydrofolate reductase mRNA from methotrexate resistant KB cells. J Biol Chem 260: 3006-3014, 1985.
31. 31. Evans RM, Laskin JD and Hakala MT, Assessment of growth limiting events caused by 5-fluorouracil in mouse cells and in human cells. Cancer Res 40: 4113-4122, 1980.
32. 32. Macdoc-Jones H and Bruce WR, On the mechanism of the lethal action of 5-fluorouracil on mouse L cells. Cancer Res 28: 1976-1981, 1968.
33. 33. Miller EM, Wilson JF and Fischer PH, Folinic acid alters the mechanism by which dipyridamole increases the toxicity of fluorouracil in human colon cancer cells. Proc Am Ass Cancer Res 28: 326-331, 1987.
34. 34. Schwartz J, Alberts D, Einspahr J, Peng YM and Spears P, Dipyridamole potentiation of FUDR activity against human colon cancer in vitro and in patients. Proc Am Soc Chem Oncol 6: 83-87, 1987.
35. 35. Finnan PJ, Koklitis PA, Chisholm EM and Giles GR, Comparative levels of tissue enzymes concerned in the early metabolism of 5-fluorouracil in normal and malignant colorectal tissue. Br J Cancer 50: 711-715, 1984.
36. 36. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW, Participation of p53 in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
37. 37. DiLeonardo A, Linke SP, Clarkin K and Wahl GM, DNA damage triggers a prolonged p53-dependent G1 arrest and long term induction of Cip1 in normal human fibroblasts. Genes Development 8: 2540-2551, 1994.
38. 38. Kuerbitz SJ, Plunkett BS, Walsh WV and Kastan MB, Wildtype p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci 89: 7491-7495, 1992.
39. 39. Bond JA, Wyllie FS and Wynford-Thomas D, Escape from senescence in human diploid fibroblasts induced directly by mutant p53. Oncogene 9: 1885-1889, 1994.
40. 40. Lowe SW, Ruley EH, Jacks T and Houseman DE, P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
41. 41. Lowe SW, Schmitt EM, Smith SW, Osborne B and Jacks T, p53 is required for radiation induced apoptosis in mouse thymocytes. Nature 362: 847-849, 1993.
42. 42. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML and Wyllie AH, Thymocyte apoptosis induced by p53 dependent and independent pathways. Nature 362: 849-852, 1993.
43. 1. Cancer Res 55: 2404-2409, 1995.